Interleukin-5 Antagonist [EPC]

688 reported adverse events

Drugs of this class: MEPOLIZUMAB RESLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-5 Antagonist [EPC] class:

# Side effect Count
0 ASTHMA 12947
1 DYSPNOEA 10802
2 WHEEZING 7232
3 PRODUCT DOSE OMISSION ISSUE 6882
4 COUGH 5183
5 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 5093
6 DRUG INEFFECTIVE 4798
7 PNEUMONIA 4750
8 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 4281
9 FATIGUE 3188
See all common reactions for Interleukin-5 Antagonist [EPC]

Drugs of the Interleukin-5 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 TOTAL LUNG CAPACITY INCREASED 187 0.6875
1 ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME 261 0.4990
2 REVERSIBLE AIRWAYS OBSTRUCTION 226 0.4449
3 VITAL CAPACITY DECREASED 184 0.4107
4 TOTAL LUNG CAPACITY ABNORMAL 153 0.3933
5 HYPOCHOLESTEROLAEMIA 138 0.3909
6 PULMONARY VASCULITIS 189 0.3513
7 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS 692 0.3390
8 EOSINOPHIL COUNT ABNORMAL 232 0.3106
9 BRONCHOPULMONARY ASPERGILLOSIS ALLERGIC 272 0.2934
See all enriched reactions for Interleukin-5 Antagonist [EPC]